Structure-based optimization of aldose reductase inhibitors originating from virtual screening (Q27654218)

1

0 references

Holger Steuber

2

0 references

Matthias Zentgraf

3

0 references

Mirko Altenkämper

4

0 references

Regina Ortmann

5

0 references

Johann Perruchon

6

0 references

Martin Schlitzer

Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications

8

0 references

publication date

May 2009

0 references

published in

ChemMedChem

0 references

volume

4

0 references

issue

5

0 references

page(s)

809-19

0 references

cites work

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

New insulins in the treatment of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

The pharmacology of diabetic complications

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Altered phosphate metabolism in the intact rabbit lens under high glucose conditions and its prevention by an aldose reductase inhibitor

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Diabetes mellitus, hypertension, and cardiovascular disease: which role for oxidative stress?

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Advanced protein glycosylation in diabetes and aging

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Zenarestat. FK 366, FR 74366, FR 901366

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Recent studies of aldose reductase enzyme inhibition for diabetic complications

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Aldose reductase in diabetic microvascular complications

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Probing flexibility and "induced-fit" phenomena in aldose reductase by comparative crystal structure analysis and molecular dynamics simulations

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

A potent aldose reductase inhibitor, (2S,4S)-6-fluoro-2', 5'-dioxospiro[chroman-4,4'-imidazolidine]-2-carboxamide (Fidarestat): its absolute configuration and interactions with the aldose reductase by X-ray crystallography

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

High-resolution crystal structure of aldose reductase complexed with the novel sulfonyl-pyridazinone inhibitor exhibiting an alternative active site anchoring group

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Ultrahigh resolution drug design I: details of interactions in human aldose reductase-inhibitor complex at 0.66 A

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Virtual screening for inhibitors of human aldose reductase.

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Structural and thermodynamic study on aldose reductase: nitro-substituted inhibitors with strong enthalpic binding contribution

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Processing of X-ray diffraction data collected in oscillation mode

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Crystallography & NMR System: A New Software Suite for Macromolecular Structure Determination

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Improved methods for building protein models in electron density maps and the location of errors in these models

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

PROCHECK: a program to check the stereochemical quality of protein structures

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Non-thiol farnesyltransferase inhibitors: N-(4-tolylacetylamino-3-benzoylphenyl)-3-arylfurylacrylic acid amides

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021

Non-thiol farnesyltransferase inhibitors: utilization of the far aryl binding site by arylthienylacryloylaminobenzophenones

1 reference

https://api.crossref.org/works/10.1002/CMDC.200800410

7 January 2021